Since their introduction approximately 15 years ago, GLP-1 RAs have solidified their role as a key class of glucose-lowering agents, with continued potential for expansion in treating T2DM and possibly other diseases [40]. This evidence concerns the gene GCG and type 2 diabetes mellitus.